Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03265769
Other study ID # Atadek2017/13
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 8, 2017
Est. completion date July 8, 2021

Study information

Verified date September 2021
Source Acibadem University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pecutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is most commonly performed using bilateral transfemoral access and 8 French guiding catheters. However, transfemoral approach (TFA) is associated with higher risk of vascular access complications.5 It has been reported that using transradial approach (TRA) reduces vascular complications and may be associated with a better clinical outcome. Transradial access is also used in complex PCI interventions.There is a growing body of evidence regarding the use of this approach also in CTO procedures. In available literature, all studies comparing TRA vs. TFA in CTO consisted of single center and single operator experience. Besides, none of them is randomized. To fill in the gap, we sought to examine the technique and outcomes of transradial vs. transfemoral CTO PCI in a contemporary multicenter randomized study.


Description:

All consecutive patients referred for CTO PCI between August 2017 and July 2021 at Acibadem University Kocaeli Acibadem Hospital, Kocaeli; Erciyes University Medical Faculty, Kayseri; Istanbul University Cerrahpasa Medical Faculty, Haseki Cardiology Institute; Istanbul; Memorial Bahcelievler Hospital, Istanbul were screened for enrollment in the study. The exclusion criteria included: (a) any acute coronary syndrome within 3 months; (b) severe heart failure issues; (c)severe renal failure (d) failure to provide written informed consent.The radial access group consisted of patients with single or bi-radial approach. Any femoral artery puncture was considered a femoral case. For example, a crossover from any radial to femoral access was considered a femoral case. Procedures were performed by 4 interventional cardiologists, who are dedicated radial operators, at 4 different centers. The protocol was approved by the institutional review board and all patients provided written informed consent.


Recruitment information / eligibility

Status Completed
Enrollment 610
Est. completion date July 8, 2021
Est. primary completion date July 8, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Any patient with coronary total occlusion >3 months and indication for intervention Exclusion Criteria: - Acute coronary syndrome within 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
radial access site
radial route
femoral access site
femoral route

Locations

Country Name City State
Turkey Acibadem University Istanbul
Turkey Haseki Cradiology Institute Istanbul
Turkey Memorial Hospital Istanbul
Turkey Erciyes University Kayseri

Sponsors (1)

Lead Sponsor Collaborator
Acibadem University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedural success Technical success without any in-hospital event 24 hours
Secondary Major access site complications Major bleeding, vascular complication requiring intervention and hematomas = 10 cm 24 hours
See also
  Status Clinical Trial Phase
Completed NCT01205776 - EXCEL Clinical Trial N/A
Completed NCT01205789 - EXCEL Clinical Trial (Universal Registry) N/A
Completed NCT01249027 - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Completed NCT01086228 - XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan N/A
Completed NCT01120379 - XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort) N/A